EPCAM and cancer: Together, these characteristics enhance the anticancer activity of EpCAM-ReTARGTPRIFNαR149A, leading to improved cancer cell lysis, which corroborates findings by Hervas-Stubbs et al., who showed that treatment with IFNα during the in vitro expansion of anti-CMV CD8pos T cells increases IFNγ production and enhances their cytolytic capacity [17].